当前位置: X-MOL 学术N. Engl. J. Med. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Good News and Bad News - 4CMenB Vaccine for Group B Neisseria meningitidis.
The New England Journal of Medicine ( IF 158.5 ) Pub Date : 2020-01-23 , DOI: 10.1056/nejme1916440
Lee H Harrison 1 , David S Stephens 1
Affiliation  

This article has no abstract; the first 100 words appear below.

Neisseria meningitidis remains a major cause of meningitis, sepsis, and other serious infections globally. Almost all meningococcal infections are caused by one of six capsular groups (A, B, C, W, X, and Y) that are distinguished by different biochemical compositions of the polysaccharide capsules. Over the past two decades, the use of meningococcal capsular polysaccharide–protein conjugate vaccines has led to major successes in the prevention of invasive meningococcal disease. For example, the introduction of monovalent meningococcal capsular group A conjugate vaccine in the “African meningitis belt” (from Senegal to Ethiopia) and meningococcal group C conjugate vaccine in the United Kingdom . . .



中文翻译:

好消息和坏消息-B组脑膜炎奈瑟菌的4CMenB疫苗。

本文没有摘要。前100个字显示在下方。

脑膜炎奈瑟菌仍然是全球脑膜炎,败血症和其他严重感染的主要原因。几乎所有的脑膜炎球菌感染都是由六个荚膜组(A,B,C,W,X和Y)之一引起的,这六个荚膜组的多糖胶囊的生化成分不同。在过去的二十年中,脑膜炎球菌荚膜多糖-蛋白结合疫苗的使用在预防浸润性脑膜炎球菌疾病方面取得了重大成功。例如,在“非洲脑膜炎带”(从塞内加尔到埃塞俄比亚)中引入了单价A型脑膜炎球菌荚膜结合疫苗,在英国引入了C型脑膜炎球菌结合疫苗。。。

更新日期:2020-01-23
down
wechat
bug